Mymetics Corporation Announces the Appointment of Dr. Stanley Plotkin as Chairman of the Scientific Advisory Board

Mymetics Corporation Announces the Appointment of Dr. Stanley Plotkin as Chairman of the Scientific Advisory Board and Election of New Members

EPALINGES, Switzerland, Sept. 9, 2009 (GLOBE NEWSWIRE) -- Jacques-Francois Martin, newly appointed President and CEO of Mymetics Corporation (www.mymetics.com) (OTCBB:MYMX), announced today the progression of Mymetics' Scientific Advisory Board with the appointment of Dr. Stanley Plotkin as the Chairman of the revised Scientific Advisory Board.

"The role of the Scientific Advisory Board, under the chairmanship of Dr. Plotkin, will be to provide expert scientific advice as well as to provide
assistance in raising funds from foundations, governments and other nonprofit organizations," stated Jacques-Francois Martin, "We look forward to the first meeting of the Board that will be held at the AIDS Vaccine Conference in Paris in October 2009."

The following members, well known at an international level, have been appointed to the Scientific Advisory Board effective immediately. Full biographies will be soon available at www.mymetics.com

Chairman of the Scientific Advisory Board - Dr. Stanley Plotkin, Emeritus
Professor Wistar Institute, consultant to Sanofi Pasteur, developed the rubella
vaccine in 1960s; worked extensively on the development and application of other
vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus as
well as senior roles at the Epidemic Intelligence Service, U.S. Public Health
Service; Aventis Pasteur (medical and scientific director); and Sanofi Pasteur
(executive advisor).

Vice Chairman of the Scientific Advisory Board - Dr. Marc Girard, has over 20
years of experience in the development of an HIV vaccine, is a past Director of
the Merieux Foundation and a consultant to the WHO and former Chairman of
EuroVac (European Consortium for HIV vaccine).

* Dr. Morgane Bomsel, Cochin Institute, France.
* Dr. Ruth Ruprecht, Harvard University, Dana Farber Cancer
   Institute, Boston, USA.
* Dr. Ronald H. Gray, Johns Hopkins University, Baltimore, USA.
* Dr. Malegapuru William Makgoba, University of KwaZulu-Natal,
   Durban, South Africa.
* Dr. Souleymane Mboup, Cheikh Anta DIOP University, Dakar, Senegal.
* Dr. Juliana McElrath, University of Washington, Seattle, USA.
* Dr. Odile Puijalon, Institut Pasteur, Paris, France.
* Dr. Caetano Reis e Sousa, Cancer Research UK, London, UK.
About Mymetics

Mymetics is a Swiss based, U.S. biotechnology company, focused on the
development of the next generation preventative vaccines, using virosomes as a
vaccine delivery platform combined with rationally designed antigens that induce
protection acting on early transmission and infection events, including the
mucosal immune response as a first barrier against the infection. Mymetics
currently has 5 vaccines in development: HIV, Influenza, Respiratory Syncytial
virus (RSV), Malaria and Herpes Simplex Virus (HSV).

In February 2009, Mymetics announced the success of its pre-clinical HIV/AIDS
viral challenge. The proven success of their vaccine in primates could not have
been more compelling: the vaccinated group either proved resistant to the virus
or remained at a non detectable level, whereas the non-vaccinated animals were
completely infected. This success further prompted Mymetics to move forward its
product into clinical development, with the expected launching of Phase I in
December 2009.

The Influenza vaccine candidate is subject to a license agreement with Solvay
Pharmaceuticals.

The RSV vaccine has finished pre-clinical studies and is being evaluated by
pharmaceutical companies for partnership agreements.

Mymetics' Malaria vaccine is in Phase 1b clinical trial in Tanzania where
children and teenagers are vaccinated in a naturally endemic area. The Phase I
final report is expected in the coming month.

The HSV vaccine candidate has generated very encouraging results in pre-clinical
studies and Mymetics will seek co-development or partnership agreements with
pharmaceutical companies.

The Mymetics Corporation logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5478

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are
"forward-looking statements". Such forward-looking statements are sometimes
identified by words such as "intends", "anticipates", "believes", "expects" and
"hopes". The forward-looking statements are made based on information available
as of the date hereof, and the Company assumes no obligation to update such
forward-looking statements. Editors and investors are cautioned that such
forward-looking statements involve risks and uncertainties that could cause the
Company's actual results to differ materially from those in these
forward-looking statements. Such risks and uncertainties include but are not
limited to demand for the Company's products and services, our ability to
continue to develop markets, general economic conditions, our ability to secure
additional financing for the Company and other factors that may be more fully
described in reports to shareholders and periodic filings with the Securities
and Exchange Commission.

-0-
CONTACT:  Mymetics Corporation
          Europe
          Ronald Kempers, Chief Operating Officer
            +41 21 653 4535

Suggested Articles

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.

The actions will create a slimmed-down commercial-stage company focused on selling hepatitis B vaccine HEPLISAV-B.